Hopkinson Craig C. 4

What Happened
Craig Hopkinson, EVP R&D and Chief Medical Officer at Alkermes (ALKS), acquired 25,352 ordinary shares on Feb 5, 2026 due to the vesting of performance-vesting restricted stock units (2023 PRSUs). To satisfy related tax withholding, 7,454 of those shares were surrendered/disposed at $33.55 per share for a reported value of $250,082.

Key Details

• Transaction date: 2026-02-05 (Form 4 filed 2026-02-06). Filing was submitted the next day.
• Acquired: 25,352 shares (award/vesting; transaction code A).
• Disposed/withheld for taxes: 7,454 shares at $33.55 each, total $250,082 (transaction code F).
• Shares owned after transaction: not specified in the filing.
• Footnote: The 25,352 shares are from 2023 PRSUs with a three-year performance period ending 12/31/2025; this represents the final vesting event after pre-specified performance goals and a relative total shareholder return modifier.

Context
This was a vesting/tax-withholding event (not an open-market sale). The withholding of shares to cover taxes is a routine administrative step and does not, by itself, signal a discretionary sale or change in insider sentiment.